论文部分内容阅读
目的:探讨胆管细胞癌ROS酪氨酸激酶基因的融合,揭示胆管细胞癌的发生机制。方法:运用cDNA末端快速扩增,PCR检测,Western印迹法分析胆管细胞癌病人ROS酪氨酸激酶融合情况。结果:23例胆管细胞癌组织中2例(8.7%)存在ROS酪氨酸激酶融合,为FIG-ROS(S)和FIG-ROS(L),正常组织未发现ROS酪氨酸激酶融合。结论:胆管细胞癌病人中存在FIG-ROS酪氨酸激酶融合,其可能与胆管细胞癌的发生关系密切。FIG-ROS酪氨酸激酶融合可为初步筛查和靶向治疗胆管细胞癌提供方向。
Objective: To investigate the fusion of ROS tyrosine kinase gene in cholangiocarcinoma and to reveal the mechanism of cholangiocarcinoma. Methods: The fusion of ROS tyrosine kinase in cholangiocarcinoma was analyzed by rapid amplification of cDNA ends, PCR detection and Western blotting. RESULTS: ROS tyrosine kinases were found in 2 of 23 (8.7%) cholangiocarcinoma tissues, which were FIG-ROS (S) and FIG-ROS (L). No ROS tyrosine kinase was found in normal tissues. Conclusion: Figure-ROS tyrosine kinase fusion exists in patients with cholangiocarcinoma, which may be closely related to the occurrence of cholangiocarcinoma. FIG-ROS tyrosine kinase fusion provides a primary screening and targeted treatment for cholangiocarcinoma.